Skip to main content
TipRanks
Go Ultimate75% OFF

Huakang Biomedical Holdings Company Limited (8622) AI Stock Analysis

0 Followers
HK:8622

Huakang Biomedical Holdings Company Limited

(HKEX:8622)

Select Model
Rating:46Neutral
Price Target:HKD 0.28â–¼(-7.00% Downside)
Action:reiterated
Date:11/12/26

The score is primarily constrained by persistent losses and sustained cash burn, despite strong revenue growth and conservative leverage. Positive technical momentum provides secondary support, while the negative P/E and absent dividend yield limit the valuation profile.

Positive Factors
Strong Revenue GrowthRapid revenue expansion indicates growing demand and improving market reach, giving the company a larger base from which to develop operating scale. If sustained, this growth can support stronger earnings potential, although profitability conversion remains necessary.
Negative Factors
Persistent Operating LossesThe company remains materially unprofitable despite strong revenue growth, showing that increased sales have not yet translated into adequate operating leverage. Continued losses could limit internally funded expansion and require management to prioritize a credible path toward break-even.

Huakang Biomedical Holdings Company Limited (8622) vs. iShares MSCI Hong Kong ETF (EWH)

-80%-60%-40%-20%0%20%HK:8622-44.44%EWH+8.17%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Market Cap
HKD 154.64M
Dividend Yield
―
Average Volume (3M)
243.54K
Price to Earnings (P/E)
-21.1
Beta (1Y)
0.45
Revenue Growth
30.60%
EPS Growth
-6.86%
Country
Hong Kong
Employees
101
Sector
Healthcare
Sector Strength
51
Industry
Drug Manufacturers - Specialty & Generic

Huakang Biomedical Holdings Company Limited Business Overview & Revenue Model

Company Description

Joyzyme Group Limited operates as an investment holding firm, primarily dedicated to the research, development, manufacturing, marketing, and distribution of in-vitro diagnostic (IVD) reagents within the People's Republic of China. Its comprehensive...

Huakang Biomedical Holdings Company Limited Financial Statement Overview

Summary

Strong revenue growth and resilient gross margins are offset by persistent operating and net losses, negative operating cash flow, and recurring free-cash-flow burn. Low leverage and a stable equity base provide some support.

Income Statement

37Negative

Balance Sheet

62Positive

Cash Flow

24Negative
Financial statement breakdown
BreakdownTTMDec 2025Dec 2024Dec 2023Dec 2022Dec 2021
Income Statement
Total Revenue32.51M28.28M25.36M24.63M25.33M26.13M
Gross Profit19.92M17.77M17.07M16.09M16.91M16.46M
EBITDA-2.54M-4.17M-1.68M-2.55M188.00K-852.00K
Net Income-5.07M-5.01M-4.16M-5.78M-3.08M-4.22M
Balance Sheet
Total Assets66.21M66.64M65.22M65.31M66.40M67.06M
Cash, Cash Equivalents and Short-Term Investments39.23M41.96M36.49M32.94M33.30M36.21M
Total Debt7.66M4.96M4.08M5.14M1.88M1.78M
Total Liabilities17.09M15.46M11.17M14.30M9.88M9.36M
Stockholders Equity49.07M51.15M54.05M51.02M56.52M57.70M
Cash Flow
Free Cash Flow-7.21M-3.29M-5.05M-1.55M475.00K-4.71M
Operating Cash Flow-6.10M-2.21M-3.06M-48.00K1.29M-2.38M
Investing Cash Flow-1.88M2.32M-4.42M-1.15M-6.11M-2.06M
Financing Cash Flow5.13M4.78M6.30M1.02M2.32M-1.37M

Huakang Biomedical Holdings Company Limited Technical Analysis

Technical Analysis SentimentPositive
Last Price0.30

Price Trends

50DMA0.20Positive
100DMA0.19Positive
200DMA0.25Positive

Market Momentum

MACD0.03Negative
RSI75.27Negative
STOCH85.47Negative

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:8622, the sentiment is Positive. The current price of 0.30 is above the 20-day moving average (MA) of 0.24, above the 50-day MA of 0.20, and above the 200-day MA of 0.25, indicating a bullish trend. The MACD of 0.03 indicates Negative momentum. The RSI at 75.27 is Negative, neither overbought nor oversold. The STOCH value of 85.47 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for HK:8622.

Huakang Biomedical Holdings Company Limited Peers Comparison

Overall Rating

UnderperformOutperform
Sector (51)

Financial Indicators

HK:8622 against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
HK:0897HK:089759NeutralHKD 406.75M101.390.34%―-8.30%-44.44%
HK:0858HK:085854NeutralHKD 153.70M-0.14-154.56%―-7.12%-523.61%
Sector *51Neutral$7.86B-0.30-43.30%2.27%22.53%-2.21%
HK:0911HK:091150NeutralHKD 50.83M12.661.02%―-18.16%―
HK:8622HK:862246NeutralHKD 154.64M-21.15-10.11%―30.60%-6.86%
HK:0455HK:045542NeutralHKD 154.80M-2.21-14.55%―12.89%-2.56%
HK:1498HK:149841NeutralHKD 117.69M-3.87-21.66%―-6.71%43.14%

* Healthcare Sector Average

Performance Comparison

0%100%200%300%HK:8622HK:0858HK:0455HK:0897HK:0911HK:1498Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
HK:8622 and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
HK:8622Huakang Biomedical Holdings Company Limited0.30-0.24-44.44%
HK:0858Extrawell Pharmaceutical Holdings Limited0.05-0.03-32.91%
HK:0455Tianda Pharmaceuticals Ltd.0.07-0.05-40.50%
HK:0897Wai Yuen Tong Medicine Holdings Limited0.36-0.09-18.89%
HK:0911Qianhai Health Holdings Ltd.0.300.0415.38%
HK:1498PuraPharm Corp. Ltd.0.22-0.16-42.11%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Nov 12, 2026